"Arr
`
`
`.—.—. "—._.__..._ _
`
`mflmmlwfl'mmmm.M1343 »
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`
`March an, 1016
`THIS IS To CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
`THE RECORDS OF THIS OFFICE OF:
`
`:5?
`
`"
`
`'
`
`“A
`"
`3'
`-» {1* -
`3: ‘
`
`Ii
`
`
`
`I
`
`l.
`
`i“
`‘
`=
`
`I a
`
`'J
`
`:
`
`1
`
`U.S. PATENT: 9,254,273
`ISSUE DATE: February 09, 2016
`
`,_
`, "r ,
`
`E"
`fit?
`"I
`E§.-,
`
`I
`
`E: II. .
`g,
`
`E
`
`'
`
`"
`
`ByAuthorityofthe
`
`1' -
`Under Secretary of Commerce for Intellectual Property
`and Director of the United States Patent and Trademark Office?
`
`i
`
`
`
`
`
`ANIJRFA T BENNETT
`
`Certifying Officer
`
`
`
`w
`
`J
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 1 of 23
`
`

`

`(12) United States Patent
`(10) Patent No.:
`US 9,254,278 BZ
`Scharscinnidt et al.
`(45) Date of Patent:
`*Feb. 9, 2016
`
`U8009’25427SB2
`
`(54)
`
`(71)
`
`METHODS OF THERAPEUTIC
`MONITORING OF NITROGEN SCAVENGING
`DRUGS
`
`Applicant Horizon
`IL (US)
`
`Therapeutics, Inc, Deerfield,
`
`(72)
`
`inventors:
`
`III-nee Seharschmidt, San Franciscan,
`CA (US); Masomi Meridian-mi, Walnut
`Creek, CA (US)
`
`(73)
`
`(‘)
`
`Assignee: Harmon Therapeutics, In, Deetfleld,
`IL (US)
`
`Notice:
`
`Subject to any disclaimer, theta-m ofthis
`patem is waded or adjusted under 35
`U.S.C. 1540:) by 0 days.
`
`This patent is subject to a terminal dis-
`chimer.
`
`(21)
`
`Appl. No; 141816,674
`
`(22)
`
`(55)
`
`(63)
`
`(60)
`
`(51)
`
`Filed:
`
`Aug. 3, 2015
`Prior Publication Data
`
`Nov. 26, 2015
`US 201510335605 A1
`Related [1.5. Application Data
`Continuation of application No. 131775,”, filed on
`Feb. 22, 2013, now Pat. No. 9,095,559, which is a
`continuafion of application No. 13/417,137, filed on
`Mar. 9, 2012, now Pat. No. 8,404,215.
`
`Provisional application No. 611542,100, filed on Sep.
`30, 201i, provisional application No. 61!564,668,
`IiiedonNov. 29, 2011.
`on. C}.
`AGIKW
`.401? mm
`
`(2005.01)
`(2006.01)
`(Continued)
`
`(52)
`
`03. c1.
`CPC
`
`33/4925 (2013.01); GOINMW (2013.01);
`Y10T430'175383 (2015.01)
`(58] Field of Classification Search
`CFC
`........ A61K3U216; 601N31f221; Y10’I’
`4361175383
`USPC _.._.... 42419.2; 5141432, 433, 544, 570, 533;
`43624, 113
`See application file fin- complete semh history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`4,284,647 A
`4,457,942 A
`
`8,1981 Bmsilawetal.
`711984 Brasich
`
`(Coolinued)
`
`FOREIGN PATENT DOCUMENTS
`
`W0 WW 10"1994
`W0
`W02005f05360‘7
`62005
`
`(Continued)
`OTHER PUBLICA'HONS
`
`Amodio. P., as, “Detection ofMinimal Hepatic Encephalopathy:
`Normalization and Optimization of the Psychomen-ic Hepatic
`Month}; Scone. A Namwhologicsi and Quantified EH}
`Study,” J. Hepatol. 49:346-353. (2008).
`(Confined)
`
`Primary Examiner — Sovilha Rao
`
`(57)
`
`ABSTRACT
`
`The cement disclosure provides methods ibr evaluating daily
`ammoniaexpombascdonasinglei‘asfingammmfiahlood
`level measmemengasweilas methods thatmfizethistech-
`1:1qu to adjustmedoeageofaniungenscavcngingdmg,
`detanfinewhethertoadminisiuaniimgnscavmgingdmg,
`andtreairfitmgenretmflondisoflels.
`
`Ammmm (2013.01); A615 1011053
`(2013.01); cmmmzi (2013.01 1; 00m
`
`15 Claims, 3 Drawing Sheets
`
`n—_—
`
`g m m
`
`m ,
`s-h—aw AmmMm—qm
`
`[$1
`
`(with!
`
`III-I
`
`A“:
`
`mum/J
`"H.
`
`as
`
`A:
`
`h—u
`
`2’
`
`COPY WWW“ by USPTO [mm “19 PIES Image Databaseon 0312112016
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 2 of 23
`
`i
`
`l
`
`

`

`US 9,254,278 BZ
`
`Page 2
`
`(51)
`
`Int. Cl.
`461K SWIG
`4613' W
`Gmwjimz
`Go!” 33”,
`
`(2006.01)
`(2006.01)
`mm)
`(man
`
`(56)
`
`Emma“ Cited
`
`.
`
`U.S. PATENT DOCUMENTS
`.
`Ssmrrl
`Bum-1w
`512000 Btu-iith
`712000 Brusilow
`412001 Essen
`112012 Levy
`312013 Sohmchmidletsl.
`212014 Schmidt
`712015 Lee
`1012003 Summer
`1112004 Summsretsl.
`1212005 Young
`612006 Formula
`512008 Inlau
`112010 Schalschmidl
`112010 Whnsnetal.
`112012 8:11ch
`812012 Loo
`812013 Schmchnridt
`1012013 Sehslschmidlo‘lsl.
`512014 Schmuhmidtetol.
`412015 Schnrsolrnridtetsl.
`412015 Sehsrsehmidtetal.
`
`j:
`6.060.510 A
`6.083.984 A
`6.219.567 Bl
`8,094,521 B2
`W215 E].
`8.642.012 112
`9,078,865 32
`200100195255 A1
`200410229948 A1
`200510273359 A1
`200610135612 A1
`200810119554 A1
`201010008859 A1
`2010'001620’1 A1
`201210022157 A1
`201210220661 A1
`201310210914 Al
`201310281530 A1
`201410142186 Al
`201510094273 A1
`201510105469 A1
`
`FOREIGN PATENT DOCUMENTS
`
`612006
`“20061056794
`W0
`1:200?
`W020071005633
`W0
`"112009
`“10200910314714
`W0
`1112009
`W020091134450
`W0
`312010
`91020101025303
`WO
`312012
`“1020121023620
`W0
`4120 13
`W0 WNW-18558
`1012013
`W0
`W020131158145
`OTHER PUBLICATIONS
`
`ANDA Notice [ell-er, Par Phsnnacartieal, 113:. to Hyperion Thera-
`patties. inc... Rs: Glycerol thyl'bmynh 1.1 gmhslorsl liquid; US.
`Pat. Nos. 8,404,215 and 8,“;012 Notice of Paragraph IV Catifi-
`cslion Msr. 12. 2014.
`stsj. J. 3.. er sl.. "Review Article: The Design ofClirlical Trials in
`Hepatic Encephalopathy—An WWI-l Society for Hepatic
`Encephalopeflly and Nitrogen Melnbolim (BEEN) Consensus
`Easement." Aliment Pharmsool 111a. :13 (3539047 (2011).
`Barsolri.MessuremesrtofAnumsisinBlood.1381.Pedisfice.
`511-820 (2001).
`dehaw. et I1..TmtofCflbamyl Phosphate Synthetsso Defi-
`ciencywiflr KemArrslogles ofEsasntislArnino Acids, 292 The New
`Elglulu. Medicine, 1085 ' 90 (19115}.
`Bshhsw,M.Ln.sl..Altemstinsflrwny11senpyfiorUmCycle
`Disordsr: Thronme Later, 1‘18 .1. Pediatrics 345 (2001).
`Blair, Dluu. Blaslrovics. Gibson (sdimrs). Physician's Guide to the
`stsnlory Diagnosis ofMuholio Dim 261-276 (21] ed. 1996).
`Bler', A '12, at all "Hepatic Encqflnloplflry," Am. J. 6mm].
`96(7):!968—1976 (2001 ).
`Bullinn. AB.
`et
`a1" Long-T Tmt will: Sodium
`PhenyWeinOmiflsineWnylase-Deficienthfienls. '12
`Molecule: Genetics and Metabolism 351-355 (21101).
`Carrillch M..
`lnrhrces Apoptosis in Human Prostate
`Cancer and is More Potent than Phenylscelsse. 2 Clinical Cancer
`Research 3‘19 (1996).
`(huluoci, MA. d al.,APhrrse]Cljniu1 and Pharmacological Evalu-
`ation of Sodium Phenylbutyrste our on 120-11 Infilsion Schedule, 7
`Clin. Cancer Res. 3047 (2001).
`
`Center for Drug Evaluation and Research. Clinical Pharmacology
`MBiophsrmscultics Review forNewDrugApplicstion No. 20-645
`(Amrmnum) (2005).
`‘
`I
`Center-for DrugEvslustlondeeaesmLLabdmgforNemeg
`Application No. 20-645 (W) (2005).
`Carrier for DrugEvslustion and Research. Medical ReviewforNew
`Drug Application No. 20-645 (AmnonuJO) (2005).
`cam, Z.ets1.,Trihrtyfln:AProdmg ofButyr-ic Acidfor Potential
`Clinical Application in Difieremisfion 111cm. 54 Cancer Research
`3494 (1994).
`ClagA. sLaIII-Iyporammnmiainflle ICU. 132 Chen 1368 (2007).
`.
`.
`.
`Coll-Inn A-F- ell IL. Oral Sodium Phenyllmysste nor-spy m
`Homozygous Bda'l'hllusemia:AC1inical Trisl.8§ 31001143
`(1995).
`Cons, H. 0.. er a]... “Live Physiology and Disease: Comparison of
`Lscorloso and Nsomycin in the Treatment of Chronic Palm-Sys-
`temic Encephalopsihy. A Double Blind ControlledTr-isl,“ Gunner:-
`rlsrology 72013573683 (1977].
`Cordobs, J., "New Assam or Hepatic Encqshslopsflry,” Journal
`of Herpetology 54: 1030-1040 (201] ).
`Dsmsus, D. et sl.. plurme slursmlse Depletion in
`Humans: Effect on Lorraine Metabolism. 5 Am. J. of Physiology:
`Endocrinology sndMetabolism E801 (1998).
`Dias. 6.1L, eta1.. “AmmonisComrol andeme Orrhcome
`Among Urea Cycle Disorder Patisnss Treated. wifll Glycerol
`Phonyhtyrate," Hepslology 57(6y2171-2179 (2013).
`DMMAmndLeonard. J.
`., loserouuentfllness inhborn Errors
`“Intermediary Metabolism. 67 Ardrhms of Disease in Childhood
`1387 (1992).
`Dow, G. at a], Induction of Fetal Hemoglobin Prcdrmion in Sub-
`jectswillr Sickle CellAnominbyOl-al Sadlme 54
`Cancer Research 3494 (1994).
`E1110. F- 61 111.. Clinical maifwutions ofIslam Errors offlre Urea
`Cycle and Related Metabolic Disorders During Childhood. 134 J.
`Nimition 16058 (2004).
`EruupesnMerlicinesAgelrcy,AsnmI: Srmmyofkodrsettflrarss-
`lerl'stics for Ammousps.
`Emopsan Medicines Agency, European Public Assessmenr Report
`filmmary for EllePublic forAmmonsps (2009).
`European Medicines Am. Scientific Discussion forAmnronaps
`(2005).
`w Medicines Agency. Scientific Discussion 001' Cube.qu
`(2
`.
`FDA Label for Caruso. seven pages. (Max. 2010).
`Peillet. F. and Inboard. J.V., Alternative Pathway 'I'lrerapy lb: Urea.
`Cycle Disorders. 211.1nher.Metah.Dis. 101-111 (1998).
`Feull-Fonseu, M. L.. Sodium Benzeste new” in Children with
`InbomEnnrsofUmaSymhuia‘. Efl'ecton CmiflnoMflnbolllmlfld
`Amonis Nitrogen Remvsl. 5? Biochemical and Molecular Medi-
`cine 31(1995).
`Forenci. 1)., $01., “Hepatic Emophuhpnthy—MifiomNomsmla-
`Fins] ReportoflhsWorking
`Psrlyat the rlmwmdmyemorauoomw. Wanna.
`I998.” Hepalology 35:716-721 (2002).
`Pmandes, Snuduhny. Bugle (editors). Intern Metabolic Diseases
`Diagnosis and Treatment, 219-222 (311 ed. 2000).
`Geraglrty. MI. ml Brusilow. s.w., Disorders of the Urea Cycle. in
`Liver Disesse inCllildNn 82? (El. Suchy et s].| eds. 2001).
`Ghshril. M. etsl.."Glyoorol Phulylhulmte in Pdierrls will: Cir-rim-
`sis and Episodic ansfic Encephalopathy: A Pilot $0.10)! oszfer
`andBfliectonVcnousAnnmnia Concentration," Clinical Pharmacol-
`033 in Drug Development 2(3): 273-234 (2013).
`Gilbert. .i.ets.l.,APhsse1 Dose Escalationsnd Biosvsilsls'litysméy
`ofOsrsl Sodium Phenyillutyrate in Patients will: Reflector-y Solid
`‘llrmor Malignaneies. '1 Clin. Cancerllesoaloll 2292-2300 (2001).
`Gore. S. otal.. Impactofthc Putative Difl'srsntisfingAgsnlSodium
`Phenyle on Myelodysplsstic Syndromes and Acute Myelcirl
`Leukemia. '1 Clin.Csnoor Res. 2330 (2001).
`Gram-ran, A.L. et al., Neurological Implications of Uses Cycle Dis-
`orders.30.i.lohorith1etabDis.865(2007).
`Hasasnein, T.
`1.. at sl., "Randomized Controlled Study of
`Elm-acorporoal Allan-nil: Dialysis liar Hepatic Encephalopathy in
`Advanced Cirrhosis," Heparorogy 461853-1862 (2007).
`
`Copy provided by USPTO hour the PIES Image Database on 0312112016
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 3 of 23
`
`

`

`us 9,254,270 02
`Page 3
`
`{56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Hasslnoin, '1'. 1.. Hal..‘1nnoductionto the anatic Encephalopathy
`Scoring Algorithm (HESA)? Dig. Dis. Sci. 53:529-538 (2008).
`Hasaanein. T.. et al.. "Performance affine Hepatic Enosphalopaflry
`Scoring Algorithm in a Clinical Trial of Patients Will Cirrhosis and
`Severe Hepatic Encephalopamy.” Am. J. Gastroenterol. 1114:1392-
`1400 (2009).
`Hondeetsl“ SlsweasfislehnmtnfSevm Elmer-uh
`UsingSodhunPhenfisoethmPrepsrediu 11001103le
`25 Biol. Pharm. Bull. 1244 (2002).
`International Search anrtandWrittenOpinion firPCTJUSflQa’
`30362, mailedMsr. 2. 2009. 11 pages.
`International Search Report and Written Opinion for PCI'IUSZODW
`055256. mailed Dec. 30. 2009. 13 pages.
`Inter-Panes Review ofus Pat. No. 3.404.215.
`later Panes Review ofU.8. Pat. No. 8,642,012.
`Klepr S. etal.,UreaCycleDisorde1-a. 5 Clarent'l'realmentOpfiona
`in Nesuoloy 309-319 (2003).
`Klimt, K. and Ishizaki, T., Dose-Dependent Pharmaookinetios of
`Banzai: AddFollmfingOmanflniIrsfion ofSodinm Benzoalae to
`Humans. 41 Eur. J. Clin. Phsmsaool. 363 (1991).
`Lee, B. and Gals, 1'. Lens-Term floatation ofUrea Cycle Disorders.
`1238 J. Pediatrics 862 (2001).
`Lee. B. et al.. Cmsidflsfiomin theDiflScult-to—ManageUreaCyclo
`Disorder Patient. 21 Crit. Care Clin. 519 (2005).
`Lee, 13., ota1.. Winemmmm) Control inUresCycle
`Disorder (UCD) Patients: A Predictive Model,” Oral Abuser Plat-
`20 3.
`fiorInWmaBiochemial Genetics. PhomiaAZ.Ma1-.22.
`Leonard, J.v.. Urea Cycle 1313mm. 7 Semin.Nenato1.27 (2002).
`Lizardi—Cemem, J. et al.. Hepatic Encephalopathy A Resins. 2
`Annals of qusiology 122-120 (2003).
`MaestriNE, etal.,PloapectivetreatmentofLu'eacycle diaosdm.J
`Paediatr- 1991;119:9221-9213.
`Maestri. N-E.. d: al.. Long-Team Survival of Patients with
`Synthetaae Deficiency. 121' 1. Pediatrics 929
`'
`(1993).
`Maestri. N. F... Long-Term mutant of Girls with Orni‘lline
`Transoarmease Deficiency. 355 N. E1131. J.Mer1. 855 (1996).
`Majeerl, K, Hypermunnnemia. eMedicinaoom (Dec. 2001).
`Mariti. J.C. «al.. Elena'th Improves Nitrogen Disposal vinm
`Alta-native Pathway without Elieiting an Increase in Romain Break-
`downandcmliminConholandOmiflaineTrsmcarbamylm
`Deficient Patients, 93 Am. J. Clin. Nutr. 1248 (2011).
`lefiymmoneoflainPediahieCflniwARefiwof
`Ornithine Tranacarbamylase Deficiency (GICD) Based on ourCeee
`Studies.“ MM 160 (2004).
`McGuire, EM. ets1.. Phamlaco‘kinelic (PK)andSafetyAns1yseaof
`a.de Ammaia-RedocingAaentin HmlfllyAdullaandPafienta
`will! Cirrhosis,
`Thfi'apemius. poster. one page (2009).
`Miatani. N. at al.. Hypermgininemia: Clinical Cornea and Treat-
`naeatwithSodintexmostosndeestylmeficMSBrainmd
`Development 555 (1933)
`MokhuannLM.etal.,(2013)“ElmtedHenylaooticAcidLevelsDo
`Hot ConclataewithAnverse Events in PatimawithUreaCycle Dis-
`orderso rHepstic Encephalopsflsyand CanBoPredictodBasedonine
`Plasma PM to PAGN Ratio," Mol Genet Metab 110(4):44§-453.
`Mokhunni, M.. et a1., (2012) ‘UfinaryMW as
`Dosing Biomsrker for Patients wifi Urea. Cycle Disorders.“ Mol
`Genet Metal) 107(3):308-314.
`Monteleono. IPR. et al.. (2013) "Population Pllmnaookimtic Mod-
`eling and Dosing Simulations ofN‘mosen-Scavenging Cornpounds:
`Disposition of(flyoerol Phenylbutyrste and Sodium Phenyllmtyrate
`inAdnltand Pediatric WwimvreaCycleDismdes-sfl. Clin.
`Pharmacol. 53(7): 699—710.
`Munoz, S. 1.. “Hepatic Encephalopathy.” Med.C1in. N. Am. 92:795-
`312 (2009).
`Nasaogne, M.C., UreaCycleDefecta: Managementanfl 011mm, 28
`J. Inherit Metab. Dis. 407 (2005).
`
`New England Consortium ofMeubolic Programs. Acute Illness Pro-
`tocol: Urea Cycle Disorders: The Infanthhild with Argininnauc-
`cinateLynaeDeficimxadsptedfiomSmeMandTnchman. M.
`Proceedings ofsCensenanConfemsce fertile Management of
`Monte withUrea Cycle Disorders, 138.1. Peels. Suppl. 56 (2001).
`New England ConsorfiumofMetabolic Programs. Acute Illness Pro-
`toool: Urea Cycle Disorders: The Inlanthth with Ciuullinemia.
`sdapled from Simmer, MandTuchman, M. ProceedingsotfaCon-
`snnsuaConfcrenoe 1'0:kade withUmCch
`D1son1ers.138 J. Pods. Suppl. 36 (2001).
`Newmarlr, H. L. andYotmg. W. C.. Bulyrale and Phenylanetste as
`Agents: Practical Problems and Oppomnitiea, 22 J.
`Cellular Biochemistry 247 (1995).
`Ortiz 111.. «al.. “Development ofaCliaical Hepatic Encephalopathy
`StagingScsle,”AlimentPhs1-n:a.eol Titer 26:859-807 (2007).
`Par Humid, Inc‘s Initial Imralirlity Contentions and Non-
`[amusement Contentions ior US. Pat. Nos. 8,404,215 and
`3.642312.
`Parsons-Smith. B. G.. etal., “The Eocth in Liver
`Disease." Lancet 273:867-371 (19 57).
`Phuplunich. S. et al.. Onl Sodium Plienylbmynle in Patienls with
`Roclumt mm Gliomas: A Dose Escalation
`and
`Pbarmacologic Study, Nuns-Oncology 171' (2005).
`Plaphaupwj.“ 01:01.. ThreeCasesoflntmvenous SodiumBenzoate
`and Sodium Phenylaoelate Toxicity Occurring in the Transmit of
`Acute Hyperamonemia, B J. Inherited Metabolic Disease 129
`(2000).
`Rookey. D. C.. et al.. “Randomiud, Controlled. Double Blind. Study
`of Glycerol Phenfibutyrate in Patients with Cirrhosis and Episodic
`Hepatic Encephalopathy,” anslsology 5024001) (2012).
`Salem. M” et 01.,
`Log to Assess anatic
`Encephalopathy" Aliment Pharmcol The]: 35(8):913-920 {2012).
`Scientific Discussion in: Ammps. BMEA 2005, available at
`hup:ilwwvmanaeuropa.erocaion_Gdeocmnent_libmyf
`EPAL-éSckntifichawseionfhumaniOODZ191WC500024748.
`pdf.
`Carglumic Acid. 200mg Dispenible
`Scottish
`Tablets(Carbag.1u®) No. 299106 (Sep. 8, 2006).
`Urinary
`of
`Seskins.
`J.W.1.,
`The
`Detennination
`Phenylacelylflutaminess PhenylaceticAoid: Studies on its Origin in
`Normal
`andChildron with Cystic Fibrosis. 35 Clin. (Mm.
`M121 (1971).
`SeamhandExamintion Report forBrifishPstemApplication No.
`GB 09155453, dated Oct. 8, 2009, 5 pages.
`Sherwin. C. et al.. The Maximum Production ofGlutamine by the
`Human Body as Measuredby'flte Ollput trimarng
`37 J. Biol. Chem. 113 (1919).
`Smith. W. et al.. “Amonia Control in Children Ages 2 Monflla
`tlmmgh SYeu-a will: UreaCycle Disorders: Comparison of Sodium
`e
`and Glycerol
`Pkwy-flatware."
`J
`Pediatr.
`162(6):1228e1234.el (2013).
`Samuel. MNOMmt ShalegiesfordleMansgemmofNeonst‘al
`Urea Cycle Disorders, 138 J. Pediatrics 3'30 (2001).
`Summar, MandTuchmn,M.,ProeeedingaofaConaansusConfas-
`once for the Mmagement ofPalienla withm Cycle Disorders. 138
`J. Pedilrics as (1001).
`Scanner; 14.. UresCycle Disordelsmem‘ew, Gene Mews, www.
`geaetestsmg (Apr. 2003).
`Summer. M. at I]., Unmasked Adult-Oasis Urea Cycle Disorders in
`the Critical Care Setting, 21 Crit. CareClio. 51 (2005).
`The National Organisation for Rem Disorders (2012). The Physi-
`cian's Guilleto Urea Cycle Disorders. at httpflfnordphyaicinnguidu.
`orghspwnhcntfuploadsim lMZa‘NORDMisLGuidLJL
`Urea_cwe_puerdeu.pdr.
`T0110. 5. at al.. Ontaonopic Liver Tranqslantation for Urea Cycle
`Enzyme Deficiency. 15 Herpetology 419 (1992).
`Tmhmao, Mu 011de1:03. M.. Bloodeels ofArnnnniannrlNilro-
`gm Emerging Amino Acids in Patients with Inherited Hyperm-
`nsenemia.66 Molecular Genetics and Metabolism 10-15 (1999).
`Unload States Patent and Trademad: Office. International Search
`Report and Written Opinion dated Jan. 16, 2015 the Pl'Il'n'USI‘llvI
`58489.
`
`copy provided by USPTO from the Pins Image Database on 0312112016
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 4 of 23
`
`

`

`US 9,254,278 B2
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`United States Patent and “Badman-k Office, Intonation! Search
`Report andWritMn Opinion fwKITi' U520 141060543 daledJan. 23.
`2015.
`Vdalrup, E. at al., “Hepatic Encephalopathy in Chronic Liver Dis-
`m2014PtaeticeGuidalinehy'theAmatican Aaaociat'innforthe
`Study ofIivet-Dlseaaes and the Etuopean Association for-tho Study
`ofdte Liver.” anasologyéfl (2):?15-1'35 (2014).
`Walsh at a1.. Chemical Abstract voL 112. No. 231144.
`on
`Welboume. T. at IL. The Efi'ecl of We
`and Patients with
`Urinaryihmmniwn Excretion in Normal
`Renal Disease. 51 J. Clin. Investigation 1852 (1912).
`Wilcken. 13.. Problems in the ManagernentofUrea Cycle Disorders.
`81 Molecular Genetics and Metabolism 85 (2004).
`Wilton. Cl. et ah. PlasmaGtutsm‘toe momma Concentrations
`in Omidtins Csrbsmoylttaosferase Deficiency and Citrulllnaetnia.
`24 J. lulleritedeabolic Disease 691 (2001).
`Wright. 6.. et at. Management of Hepalic Encephalopathy. 2011
`Intemaliorna] Journal of Hapatology 1 (2011).
`Wright. R. Review: Nih'ogau Mon: ThreeEnd Prodiaota, Many
`Phyaiologieal Roles. 193 J. Experimental Biology 273 (1995;
`Yajirns. at al. Diurnal Fluctuations ofBlood Ammonia Levels in
`Adttlt-Typecitmllinemia, 137 Tokulut J. Edeed, 213-220 (19).
`“I. Ryan andPotter, Murray: Diagnosis ofUm Cycle Disorders in
`Adulthood: Late-Onset Cathamyl Phoaphate Synfltetasa 1 Deli-
`ciency. T MUMJ 30 (2010).
`hitdltofl’, M. et al., In Vivo Nitrogen Metabolism in Ornithina
`Transcatbanrylase Deficiency 93 J.Clin. Invest. 2167 (1996).
`Zeitliu.P..NovelPharmacologicTherapioaforCyatic Fibrosis. 1031'.
`Clinical Invwfiytion 447' (1999).
`Batrhttw, ML. at al. (Aug. 1981) “NewAppt-oaohes to tho Disgnosis
`and Treatment of Inbom Errors of Urea Maia." We:
`amuse-297.
`Babe, 6.. et al., (2005) 'Thmyibutyrato Increases SMN Gene
`Expression in Spinal Mumanophymm"arrmm Genet
`13:256-259.
`Brundti-Pierri. N..etal.. (2011)"Phenyllnnyrare'l'l1erapy forMaple
`Syrup Urine Disease,“ Him Mo! Gard 20(4):631-640.
`(310113.11... et a1.. (2000) "A Novel Approach for Nasopharymgeal
`Carcinmna'treatmeatUesoPhenylbutyrasoasaPmtain anassC
`Modulator: [unification tor Radiosansin'zstion and REV-Targeted
`“only,” Cit}! Wiles 621452-1453.
`Gimmes, A1500®)"Phase25ttslyof59dium?hmylhflyrste in
`AIS,"AW!) Inter-at Sclerosis 10:99-106.
`Diaz, G.A.. at al.. “Phase I! Blinded. Randomized, Crossover Com-
`parison of Sodium Phenyllatyma MBA) and Glycerol
`Phenybutyrato (GPB): Ammonia (NI-13)Control inAtlulla withUrea
`Cycle Disorders (UCDs)." Mal. Genet. Memo. 1021276, Society of
`Inherited Mmboilc Disease (SMJD) Alum.
`EangGJtotqetaL.
`(2007)“81uvivalAfier'Iteatmentwith
`Phanylaoetate and BamforUm-Cycle Disorders.” NE-tg JMasf
`35612823292.
`Gtoptnu.A. (2010)“Bnin Imagingin Urea Cycle Distndm," mt
`Generllt'etob [WSW-S30.
`Hines, R, at al..
`(211113) “Maori-Dosing with cm Sodium
`Phenylbutyrate IncreaaeaHemoglobinFin ePafientwith Sickle Cell
`Morris." Pediatr- Biaad Cancer 50357-3 S 9.
`Hogarth, P., at a1., (2007) “Sodium thylbuurrata in Huntington's
`Disease: A Dose-Finding StudyPMovDisard 22(13)1962-1964.
`Huang. H.H.. eta}... (2012) "Cannalainoid Receptor ZAgonis-mm
`lioratea Meaenteric Angiogeneais and Fame Collateral; in
`cosmic Rats,“Hm 56:243-253.
`Hyperion Therapeutics “HyperionWI Annmces Enroll-
`ment: ol’Fii-st Muslin Phase 11‘2 C11nical'Irial ofGT4P in Patient;
`with Urea Cycle Disorders“ Announcement, 1 page (Oct. 23, 2007).
`Merton-i1 E, etal.. (2004) “Pilot Trial ofPhutyllamate ‘m Spinal
`Muscular Atrophy,” Hammett! Dismd 14:130-135.
`
`Mokhtatani. M. a at. (2012) “Elevated Phertyiatoatic Acid (PM)
`Levels Appear Linked to Neurological Adverse Events in Healthy
`AdohrbtnNotinUleaCyclaDism'derCUCD) Pafients."Mal Garret
`Metal: 105:342.
`Moldova. IL, et: al.. (1957') “Synthesis ofPleuylacetylglutatnine by
`thnnnTissue.” J. Biol. Chm 29:463-476.
`Monteieono, Mot a1..(2012)“1’opuhtionphhnalwia ofGlycerol
`Phenylbutyrste (SH!) and. Sodium WWW) in
`Adult and Pediatric Patients with Ure- Cycle Diseouders.”MoJ Gent
`Mach 105343.
`0113.1. P.,etal.. (1003)“CorrelstionBetweenAmmniaLevels and
`the Savain ofHepan'cWrm. J. Med. 114433.193,
`Pam'llei 5- R. (2003) “Fetal Globin Stimulant Therapies in the Beta-
`Hemoglobinopathiea: Principles and Current Potential,"Patten-Ann
`37(5):339-346.
`Ry“. 11., at al.. (2005) “Sodium Phengdbulmtlie Prolapse Survival
`and Regulates Equestrian ofAnti-Apoptolic Genes in'I‘rlnsgenic
`Amyntrophic Lateral Sclerosis sow-Jarmm 933087-1098.
`Staten. et :11 (1993) “Dist L-ornithine-L-aapatlate therapy of
`chronic hepatic encephalopathy: results of a placebo-controlled
`double-blind Wit-lemming 28(5):856-864.
`Xie, G., et al., (2012) "Role of Difl‘erentiation of Liver Sinusoidal
`Endothelial Cells in Progression and Regression of Hepatic Fibrosis
`in Rats.“ Guru-mm [42:8918.
`European Patsttt Ofice. Extended European Search Report to:
`WEZGS completed Nov. 2, 201].
`European rum Ofliee. International Search Report andWritten
`Opinion fiat PCTMSMDQI'DSSZSS completed Dec. 18. 2009 and
`mailed Dec. 30. 2009.
`memmnmamimm.
`6310134682 datedOct. 28, 2011.
`Mutational Preliminary Mortonhtantsbilitym'hl) tin-PC]?r
`U82012ffl28620eompletedllm.4,2012andntailedonam 10.2014.
`International Preliminary Report on masman 11) for pcri
`U52012i'028620,oomp1eoadAug. 22, 2013 andntailedSsp.4. 2013.
`UnitwlsntosPahntandTndmarkO'flimtntensfionsl Search
`ReportaadWriltsn Opinionfor PCIMSZDDQIOSGSISZ mailed Mar. 2.
`2009.
`0:10:45thdekame Search
`Report and Written Opinion for PCTMSZDIZNZMID mailed Jun.
`20. 2012.
`UnifidSmantandkaOfiomIntmafionaJSenmh
`WandWrilten Opinion fir: PCUUSZO 12.54673 mailed Nov. 20,
`2012.
`UnitedSmleaPatantandTrarlamark Office, hmational Search
`RapertandWfittan Opinionth PCTIUSZDBHISGG IntailtodMar. 28.
`1014.
`IldttsruKonecki. U.. 6! IL. “AmmoniaCtmuol in Children with Um
`Cycle Disorders (UCDs); Phase 2 Comparison 01' Sodium
`thylhityrate andGlyceml thlhuyrm', Mol. Genet. Metsb.
`103:323-329 (2011).
`ANDANoficoIsttu. LupinLfitoHotiaonTherapeut'tchnc. Rs:
`Notification oflnvalldityflnenfmoahility. unitor Noninfi'ingement
`to: us Pat. Nos. 8,404,215 and 8,642,012 Perm to a
`SOSQ'XZXBXH) and (iv) of die Federal Food. Drug, and Coatnstit:
`Act. Sep. 4. 2015.
`Ahrens, M. at al.(1an.2001)."Cottsenaus Smhemont FromaConfer—
`once for the
`of Patients With Um Cycle Disorders."
`Supp. Journal ofPediatrica 138(1):Sl-S§.
`Ambrose. AM. et a1. (1933). “Further Studies on the Detoxification
`ofPlenfiaoeticAoid,"l. Bio. Chem.101:659-€75.
`Betshsvv. ML. etal. (Dec. 1980). “Treatment of Hypamnmonomic
`Corns. Caused by [about Errors of Urea Synflteaia.” J. Pediatr.
`97(6y893-900.
`Batahlw ML. at I]. (Jun. 10. 1982). "I‘m oftnbom Errors of
`Urea. Synflieais: Activafion ofAltet-native Pathways ostae Nitro-
`gen Synthesis mill-Excretion," N. Engl. J. Med. 306(23)1387-1392.
`Baishaw, ML. (1984). "I-Iyper'ammonemia," in Current Problems in
`Pediatrics, Inckhart, J.D. ed.: Yer Bonk Medical Publishers. pp.
`2-69.
`Berry, (1.1., at al.I ‘1.me hilt-gamut ofPstiontswill: Urea
`Cycle Dilol'lla‘ls,” J. Pediatrics (2001) 138:856—861.
`
`Copy provided by USPTU llorll the PIES Imago Database on 03121I2016
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 5 of 23
`
`

`

`US 9,254,278 B2
`
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`Brusilow. 3.. et al.. “Amino AcidAcylafion: A Mechanism ofNiiro-
`gcn Execution inInborn Errors oI’Urea Syniliesla." Science 2110:659-
`661 (1900).
`Bluliiflw, S. W., ofal.. “Phenylacctylgluiarnine MxyReplaceUi-eaas
`a Vehicle for Waste Nihogen Brandon! Padiasr. Res. 29: 147-151)
`(1991).
`uni-flow. aw. at .1. (Sep. 1. 1979). “New Pathways of Nitrogen
`Excwiion in lubou Enos ofUres Syniiiesis.“ Leno: 2(8140}:452-
`454.
`Bnuilow, 3.W. (Jun. 21,1984). *freahneni of Episodic Hyperm-
`rnonemiain ChildrenWith hbmnEnoisofUm Synthesis," N. Engl.
`1. Mod. 310(291630-1634.
`Bunsilow, SW. (Amendment Dated Jul. 25, 1994). “Protocols for
`Managmtoflnimlnrenti-lypersmoncmia inPstientswifll Um
`Cycle Disorders.” FDA Application in Mei-100i A New Drug ii):
`Hum Use or an Antibiotic Drug for Human Use, Fourteen pages.
`Bmsilow. 5.. et al. (1991). “Treehnent of Urea. Cycle Disorders,”
`Chapters inTresimenlofGenetic Diseasegmm. eta]. eds.
`Churchill livingstone, NewYorlc, Nchork. pp. 79-94.
`Bunilow. SW. et al. (1995). "Urea Cycle Enzymes." (manner 32 in
`TheMelsbolicandMolecularboaesoflnheriiedDiseasenm,
`C.R. et a1. eda.. MoGraw-Hill, inc. NmYork, pp. 1187-1232.
`Bmsilow. S.W., et a1. (1996).“Ll’rea Cycle Disorders: Diagnosis,
`Pafliopliysioloy,and1‘herspy,"Adv. Pediatr. 43:127-170.
`Bruailow, S.W., eta]. (1995). ‘Uree Cycle Disorders: Clinical Para-
`digmof
`nemicEnccphsiopathgq"PmyossinLisorDis-
`cases (1995) 12:293-309.
`Bruailow, S. W.. et a1.. “Restoration of Nitrogen Homeostasis in a
`Man with Orniihina 'i‘ianscaibamylase Deficiency," J. Metabolism
`[1993) 42: 1336—1339.
`Gallows“ But et a1. (1971). "Sweat and Mseeilaneous Nilrogen
`Lessee in Human Balsnoe Studies.“ J. Nutrition 101:7‘15-‘186.
`(kiloway. [11-]. el' a1. (1971]. "Variation in Endogenous Nilmgen
`Emotion and Dietary Nitrogen Ulilintion aa Deienninania of
`Human Protein Requiremenis.” J. Nun-flier: 101:205-216.
`Cnnacho. L.H. eta]. (2007,0-11Ih. Oct. 20, 2006). “prim 1 Done
`Escalation Clinical Trial of new] butyraie Sodium Adminiainred
`Nice Daily In Patients Willi Advanced SolidW" hiveat. New
`Drugs 25:131-138.
`Chang 1.5., a 0., "rm-nun ofSpinal 1mm Aimpiry by
`SodiumBniyralo.” mas 03A (2001)90(11):9008-9013.
`CflnicalTfialmGwlArchiveView ofNCTDOSSIZOOon Dec. 11, 2007
`"Dow-
`Escalation
`Safety
`Study
`or Glycny
`Ta
`(4-HenyllaityraneXGT4P} in Treat Urea Cycle Disorders” [accessed
`Oct. 5, 2009]. 4 ma.
`Combined Search and Examinationliopon mailed. on Sap. 9, 2010,
`fora-real Erilsio PateotApplicsfioo No. 1013-1682. filedimAug. 21,
`21119. six p133.
`Confined SemchsndEiiaminationRepoitmailedomoivLQ. 2009,
`mom-10min PalemApplicnlinn No. 61309155453,illedon Aug.
`21'. 2009, eight pages.
`'Coniplaint n:th infringement".MWe Inc. v.
`WWW]; Inc. FilodinUS. Dilric‘tColm forflwEalu-n
`Districtof'l'mApr. 23.2014.
`‘Con'lplaint for Patent Infi'ingcsneni’. Horizon We. line. v.
`mm mmmmmirm. Filed mus. District
`Conn torihe DialficlofNew Jersey. 00!. 19. 2015.
`Come. 3.. eta]. “Identification oiPhenylbmyrylghdmine, A new
`Metabolite ofPhenbeulyraia Metabolinn in Humans.“ Journal of
`MassW (2002) 37(6):501-590.
`Dams. G.
`at
`al.:
`“Prepantiun 91' will)!" Wald“
`phenylnlinhatiquesetlesnrednciioneneloools .
`.
`. ", Compton
`Remiusl-iebdomsdsiresDes SenaneL‘AcadnnfieDesScicncea‘
`vol. 205, Del. 13, 1937. pp. 682-684.
`Defiemri. G. etal. (1981). “Brain Metabolism ol'Amino Acidsand
`Ammonia in Patienl: will Chronic M WNW"
`[animations] 20:505-510.
`DiazI G.A.. et a1.I "Phase 3 Blinded. Ramlmimd. Crossover-Com-
`parison of Sodium Phenylhltyflte (NBPBA) and Glycerol
`
`Phenyihutyrnte (GPB): Ammonia (NI-13) Conbol in AdamswithUrea
`Cycle Disorders (UCDs)? Mol. Genet. Mash. 102:276 (2011).
`DiazG.A.ei al. “AmmniaMB) control and impruvednemmogni-
`hiveouicomeamongtneacyele disorder (UCDnuientsMeduith
`glycerol plianylhutyrate(GPB)."Mol. Genet. Meiab. 2012, 105.311.
`SIMD Abstract 24.
`Examinafion Repth mailed on Oct. 21', 2010, forUnited Kingdom
`Paoent Application No. 6309155453, filed on Aug. 27, 2009, two
`plans-
`Emcninnfion Reprtmsiled Feb. 5, 2010.!orUnited Kingdom Patent
`Application No. (5309155453, filedonAug. 27. 2009. two page.
`Examinafion Report nailed May 11. 2010. for United Kingdom
`Pam Application No. 6130915545 .8. filed on Aug. 21. 2009, one
`008°-
`FDA Label rm AmmonulO. sixteen pages (Feb. 2005;
`nine
`.
`FDA. (Aug. 2003). “Buphenyli‘b (Sodium Phwiylbutyute) Label”
`FDA Label for Bimhenyl. 6 pages.
`GaIIO‘Iky. S. (2006) “High Anumoia Levels are Associated Wiili
`Increased Modalitde Coma." Ucyclyrl Plasma. Inc.. one page.
`Gargoslqv. 5. st al. (Oct. 14. 2005). “Remus ofa Neely-two Year
`Clinical Trial: Acme, Adjunctive Musicologich Tresimeni oi'
`Hyperammonemic Episodes in Patients wilt Mcienciel
`in
`Enzymes ofiheUnea Cycle." poster, Ucyclydl'hamis. lnc., onepage.
`Gargoslw, 8. (Ann. 2. 2005). “Improved Survival of Neonates Fol-
`lowing Administration of Annnonuio (Sodium Phony! acehte &
`Sodium Benzoaoe)10%110% Injection,” SSIBMPoeier. romance.
`Ghabril. ML. oi al.. “Glycerol Phenyth (GPB) Adminilration
`in mm with Cirrhosis mi Episodic Hepatic Encephalopaflly
`(118)," acceftei‘l forpresonialion at Digestive DiaoaaeWeek, 2012.
`Gropmsn.A.L.,etsl..“l unannounme
`entiation in Sisters with Lute Onset (knifhine Transcarbomylsae
`Deficiency (OTCD] and Discordsnt Clinical Presentations,“ Mol.
`Genet. Metals. 94(1):52-60 (2000).
`(immunetsigfl HMRSIdenlifiesSympsomsticand
`Asymptomatic Subjecl: with Partial Orniflline Triniacarbainylsse
`Deficiency.” Moi. Genet. Meish 95:21-30 (2008).
`Hyperion Therapeutics. (Mar. 30, 2009). “Hyperion Therapeutics
`Announces RewltsforPhaseIISiudyinUteaCycleDism-dars.“
`locfied
`at
`1238518338? IaatviaitedonApr. 27.2011.t1neepsges.
`Hyperion Thesapeifies. (Jun. 21 2009.) “Hyperion Therapeutics
`AnnouncesRcmlianl’HIsae I Study in Psfients with Livu Cirrhosis”
`located
`atdflpflwwwhyperionnceombreasireleuelpr
`1224339116». in: viaitedonApr. 27, 2011, tin-mm
`lniiernniionalPreliminaryReporionPaeeniahiiilynniledonMan 1.
`2011, forPCIAnplicafionNo. l’C’I‘i’iJSZli111040313362l filed on Jan. 7.
`2009, seven pages.
`lniiemaiional Piefiminaryncpononl’aoeninbiliiymailed on Mar. 1,
`2011, fin: PCT Application No. PCI'IUSZEJOQIUS 5256, filed 00119.03.
`2?. 2009. six pages.
`James. MD. et al. (1972). “The Ccniussiion ofPhenylsoetie Acid in
`Mill. Sub-Human Prim and SomeOtherNon—Prinflea Species."
`Prue. R. Soc. Lindon 189425-35.
`John. BAeta1.(Msr.2009)."rheDispoeitionofHPN-lm,ANovel
`Phsmisoeuticsl Under Developneni; for Potential Treatment of
`HyperammonenlininCynomologln MW.”Msctpesufiedai
`ACMG 2009. one page.
`John. EA. et 01. (Mar. 2009). “Ibo Disposition ofHPN—lm. ANovel
`Phemmoeuticel Under Development for Pomiai Treatment of
`Hypoiammonomia, in Cynomolsus Monkeyn'MCMGZOOQ ADME,
`PM m [139%
`'
`Kassnnov. 'T.. el 01.. “New Secondary Meieboliiesofl'hewlhm
`in Humans and Rats," Drug Metabolism and Disposition (2004)
`32(1):10-19.
`Lee 01 al.. “Butyramide and Monohomin: Growth Inhibiimy and
`Diii'ezwtiating
`dnficanoer Rem, 13-. 145-150(1993).
`Lee, E et a]. (Aug. 2.009). “Dosing sndThecepcutic Monitoring of
`Ammonia Scavenging Drugs and Urinary Phenylacotylgimmninc
`@AGBDmnBioi-nsrloeri Leesonsl-‘romsPhaseZCompaiisonofa
`Novel Ammonia Scavenging Agent Willi Sodium Hienylbutymo
`(minimalism presented at ICIEM 2009. San Diego. CA. one
`P189-
`
`\—.._._.._——-——————__—__._._——_—,
`copy provided by USPTO from the Plfis Image Daiabeee on 00213015
`
`Par Pharmaceutical, Inc. Ex. 1001
`Par v. Horizon, IPR of Patent No. 9,254,278
`Page 6 of 23
`
`

`

`us 9,254,278 32
`
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Lee, B. at :1. (Aug. 2009). “Dosing and Therapeutic Moniboring of
`Amman Scavenging Drugs and Urinary Phenylncetylglolamine
`(PAGN) aaa mom-ricer: Lessons Fromal’lmez Comparison ofe
`Navel Ammonia scavenging Again with Sodium Phony] wry-m
`mnamr planted at ICIEM 2009. San Diego. CA. pasta; one
`W-
`Lee. B. et :1. (Mar. 2009). "Phase 2 Snidyofa Novel Ammonia
`Salvaging Am in Adults Win: Urea Cycle Disorders (0033)."
`obstruct mmnud stACMG 2009, one page.
`Lee.B.eta1.(Mu2009).“Pliaae28oidyofaNovelAmmonia
`Scavenging Agent in Adults will: Um Cycle Disorders (UCDs)."
`presented al ACMG 2009, seventeen poses.
`Lee. B. or 31. (Aug. 2008). "Pielirninerstuonmnl Patientswith
`UmCyole Disorders (UGO) innnOpm-Iabel,8wileh-Over. Dose-
`Eacalation Sludy Comparing a New Ammonia Scavenger. Giyou-yl
`Tri (41-th) [HPN-l on}.
`to nupnmyio (Sodium
`Phonylbutyme [roam abstract presenter at SSIEM 2008. Lisbon.
`Portugal. one page.
`Inc. B. a a1. (Sep. 2008). “Preliminary Dela on Mull Patients with
`Urea Cycle Diaordore (UGO) in an Open—Isbel, Simon-Over. Dose
`Eacala‘lion Shady Comparing aNew Ammonia. Scanner, Glycol-)1
`Tn'
`(4-Pheny1burym)
`[HPN-l on],
`In many-10 (Sodium
`PhenyltmyratcWNW u SSIEM 2008. Lisbon, Formal],
`Pom one page.
`Lee. B.